European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

D M Conti^{1

2

3}, V Backer⁴, W Fokkens⁵, P Gevaert⁶, A Peters⁷, G K Scadding^{8

9}, I Pavord¹⁰, S Lau¹¹, M Wechsler^{12

13}, X Bertels^{3

14}, G Liva¹⁵, M Doulaptsi¹⁵, E Prokopakis¹⁵, P W Hellings^{5

16

17}

Affiliations

¹ Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
² Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, Madrid, Spain.
³ The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.
⁴ Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
⁵ Department of Otorhinolarynogology and Head/Neck Surgery, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
⁶ Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
⁷ Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
⁸ Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
⁹ Division of Immunity and Infection, University College, London, United Kingdom.
¹⁰ Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
¹¹ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States.
¹³ Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, United States.
¹⁴ Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands.
¹⁵ Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece.
¹⁶ KU Leuven Department of Microbiology and Immunology, Allergy and Clinical Immunology Research Unit, Leuven, Belgium.
¹⁷ Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.

PMID: 39726672
PMCID: PMC11669716
DOI: 10.3389/falgy.2024.1517122

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

D M Conti et al. Front Allergy. 2024.

. 2024 Dec 12:5:1517122.

doi: 10.3389/falgy.2024.1517122. eCollection 2024.

Authors

Affiliations

¹ Allergy and Clinical Immunology Research Unit, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
² Escuela de Doctorado UAM, Centro de Estudios de Posgrado, Universidad Autónoma de Madrid, Calle Francisco Tomás y Valiente, Madrid, Spain.
³ The European Forum for Research and Education in Allergy and Airway Diseases Scientific Expert Team Members, Brussels, Belgium.
⁴ Department of Otorhinolaryngology, Head & Neck Surgery, and Audiology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
⁵ Department of Otorhinolarynogology and Head/Neck Surgery, Amsterdam University Medical Centres, Location AMC, University of Amsterdam, Amsterdam, Netherlands.
⁶ Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium.
⁷ Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
⁸ Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
⁹ Division of Immunity and Infection, University College, London, United Kingdom.
¹⁰ Respiratory Medicine, NIHR Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
¹¹ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
¹² Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States.
¹³ Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, United States.
¹⁴ Department of Epidemiology, Erasmus MC, Rotterdam, Netherlands.
¹⁵ Department of Otorhinolaryngology, University of Crete, School of Medicine, Heraklion, Greece.
¹⁶ KU Leuven Department of Microbiology and Immunology, Allergy and Clinical Immunology Research Unit, Leuven, Belgium.
¹⁷ Clinical Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.

PMID: 39726672
PMCID: PMC11669716
DOI: 10.3389/falgy.2024.1517122

Abstract

The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based participation was to address the educational needs of physicians dealing with asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) on the clinically relevant aspects of diagnosing and treatment with biologics. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in faculty coming from the paediatric, allergology, pulmonology, and Ear, Nose and Throat (ENT) speciality and from different continents, with more than 250 participants from over 30 countries in the first EBTC. The current report provides a comprehensive overview of key statements made by the faculty of the EBTC 2024, especially focusing on patient selection for a biologic drug, the communication with patients, the onset of biological treatment and the follow-up in routine clinical practice.

Keywords: EUFOREA; asthma; biologics; rhinosinusitis; training course; type 2 inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

See this image and copyright information in PMC

References

1. Hellings PW, Borrelli D, Pietikainen S, Agache I, Akdis C, Bachert C, et al. European summit on the prevention and self-management of chronic respiratory diseases: report of the European union parliament summit (29 March 2017). Clin Transl Allergy. (2017) 7:49. 10.1186/s13601-017-0186-3 - DOI - PMC - PubMed
1. Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al. EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. (2021) 147(1):29–36. 10.1016/j.jaci.2020.11.013 - DOI - PubMed
1. Prokopakis E, Vardouniotis A, Bachert C, Bousquet J, Carrie S, Castelnuevo P, et al. Rhinology future debates 2018, a EUFOREA report. Rhinology. (2020) 58(4):384–93. 10.4193/Rhin19.455 - DOI - PubMed
1. Fokkens WJ, Bachert C, Bernal-Sprekelsen M, Bousquet J, Djandji M, Dorenbaum A, et al. Rhinology future debates, an EUFOREA report. Rhinology. (2017) 55(4):298–304. 10.4193/Rhin17.221 - DOI - PubMed
1. Scadding G, Bousquet J, Bachert C, Fokkens WJ, Hellings PW, Prokopakis E, et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology. (2019) 57(1):49–56. 10.4193/Rhin18.076 - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

Affiliations

European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous